Literature DB >> 31889311

5-(Hydroxymethyl)furfural restores low-oxygen rheology of sickle trait blood in vitro.

Scott Hansen1, David K Wood1, John M Higgins2,3.   

Abstract

Sickle cell trait (SCT) is the benign heterozygous carrier state for the sickle variant of the HBB gene. Most of the ~300 million people with SCT worldwide will not experience any significant complications. However, accumulating evidence finds SCT associated with increased risk for the common conditions of chronic kidney disease and venous thromboembolism, and severe but rare renal medullary carcinoma and exercise-induced rhabdomyolysis. The mechanism is uncertain, but probably involves pathological rheology of SCT blood in regions of low oxygen tension, resulting from sickle haemoglobin polymerization in SCT red cells and leading to reduced blood flow and further tissue hypoxia and damage. Here, we used an in vitro microfluidic flow system to study the oxygen-dependent rheology of SCT blood and show that 5-(hydroxymethyl)furfural, a natural breakdown product of glucose and fructose-containing foods, such as fruit juices, can reduce the effects of hypoxia on SCT blood rheology in vitro, restoring near-normal flow velocities at very low oxygen. While opinions regarding the clinical significance of the risks associated with SCT are still evolving, these results suggest that a compound present in some food may provide a potential approach for managing risks that may be associated with SCT.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  5HMF; blood flow; microfluidics; rheology; sickle cell trait

Mesh:

Substances:

Year:  2019        PMID: 31889311      PMCID: PMC7150585          DOI: 10.1111/bjh.16251

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  46 in total

1.  Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications.

Authors:  Jonathan C Goldsmith; Vence L Bonham; Clinton H Joiner; Gregory J Kato; Allan S Noonan; Martin H Steinberg
Journal:  Am J Hematol       Date:  2012-02-03       Impact factor: 10.047

Review 2.  Complications associated with sickle cell trait: a brief narrative review.

Authors:  Geoffrey Tsaras; Amma Owusu-Ansah; Freda Owusua Boateng; Yaw Amoateng-Adjepong
Journal:  Am J Med       Date:  2009-04-24       Impact factor: 4.965

3.  Sickle cell vasoocclusion and rescue in a microfluidic device.

Authors:  J M Higgins; D T Eddington; S N Bhatia; L Mahadevan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

Review 4.  The current state of sickle cell trait: implications for reproductive and genetic counseling.

Authors:  Lydia H Pecker; Rakhi P Naik
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

5.  Sickle cell trait and renal disease among African American U.S. Army soldiers.

Authors:  Jiaqi Hu; D Alan Nelson; Patricia A Deuster; Eric S Marks; Francis G O'Connor; Lianne M Kurina
Journal:  Br J Haematol       Date:  2019-03-11       Impact factor: 6.998

6.  5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells.

Authors:  Osheiza Abdulmalik; Martin K Safo; Qiukan Chen; Jisheng Yang; Carlo Brugnara; Kwaku Ohene-Frempong; Donald J Abraham; Toshio Asakura
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

Review 7.  Interventions for enhancing medication adherence.

Authors:  Robby Nieuwlaat; Nancy Wilczynski; Tamara Navarro; Nicholas Hobson; Rebecca Jeffery; Arun Keepanasseril; Thomas Agoritsas; Niraj Mistry; Alfonso Iorio; Susan Jack; Bhairavi Sivaramalingam; Emma Iserman; Reem A Mustafa; Dawn Jedraszewski; Chris Cotoi; R Brian Haynes
Journal:  Cochrane Database Syst Rev       Date:  2014-11-20

8.  GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.

Authors:  Donna Oksenberg; Kobina Dufu; Mira P Patel; Chihyuan Chuang; Zhe Li; Qing Xu; Abel Silva-Garcia; Chengjing Zhou; Athiwat Hutchaleelaha; Larysa Patskovska; Yury Patskovsky; Steven C Almo; Uma Sinha; Brian W Metcalf; David R Archer
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

9.  The indirect health effects of malaria estimated from health advantages of the sickle cell trait.

Authors:  Sophie Uyoga; Alex W Macharia; Carolyne M Ndila; Gideon Nyutu; Mohammed Shebe; Kennedy O Awuondo; Neema Mturi; Norbert Peshu; Benjamin Tsofa; J Anthony G Scott; Kathryn Maitland; Thomas N Williams
Journal:  Nat Commun       Date:  2019-02-20       Impact factor: 14.919

10.  Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.

Authors:  Rakhi P Naik; Vimal K Derebail; Morgan E Grams; Nora Franceschini; Paul L Auer; Gina M Peloso; Bessie A Young; Guillaume Lettre; Carmen A Peralta; Ronit Katz; Hyacinth I Hyacinth; Rakale C Quarells; Megan L Grove; Alexander G Bick; Pierre Fontanillas; Stephen S Rich; Joshua D Smith; Eric Boerwinkle; Wayne D Rosamond; Kaoru Ito; Sophie Lanzkron; Josef Coresh; Adolfo Correa; Gloria E Sarto; Nigel S Key; David R Jacobs; Sekar Kathiresan; Kirsten Bibbins-Domingo; Abhijit V Kshirsagar; James G Wilson; Alexander P Reiner
Journal:  JAMA       Date:  2014-11-26       Impact factor: 157.335

View more
  3 in total

1.  MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.

Authors:  Melanie Demers; Sarah Sturtevant; Kevin R Guertin; Dipti Gupta; Kunal Desai; Benjamin F Vieira; Wenjing Li; Alexandra Hicks; Ayman Ismail; Bronner P Gonçalves; Giuseppe Di Caprio; Ethan Schonbrun; Scott Hansen; Faik N Musayev; Martin K Safo; David K Wood; John M Higgins; David R Light
Journal:  Blood Adv       Date:  2021-03-09

2.  Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease.

Authors:  Nagamani Vunnam; Scott Hansen; Dillon C Williams; MaryJane Olivia Been; Chih Hung Lo; Anil K Pandey; Carolyn N Paulson; John A Rohde; David D Thomas; Jonathan N Sachs; David K Wood
Journal:  Biomacromolecules       Date:  2022-08-09       Impact factor: 6.978

Review 3.  Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine.

Authors:  Peter Kubatka; Alena Mazurakova; Lenka Koklesova; Marek Samec; Juraj Sokol; Samson Mathews Samuel; Erik Kudela; Kamil Biringer; Ondrej Bugos; Martin Pec; Barbara Link; Marian Adamkov; Karel Smejkal; Dietrich Büsselberg; Olga Golubnitschaja
Journal:  EPMA J       Date:  2022-08-15       Impact factor: 8.836

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.